LEO Pharma

Views & Analysis
Almirall looks for action in eczema

Almirall gets in on the eczema action

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall wants a piece of the action.

Digital
Deep Dive Access and Commercialisation

Deep Dive: Access and Commercialisation

In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he

News
Gitte Aabo

LEO Pharma acquires Bayer’s dermatology unit

Danish LEO Pharma announced yesterday (July 31st) that it has entered a binding agreement to purchase Bayer's global prescription dermatology portfolio, in line with its goal to help 125 mi

Views & Analysis
eye-on-innovation-16x9-18_07_2018

The sky’s the limit for LEO Pharma's R&D hub

As part of pharmaphorum’s eye-on-innovation series of interviews, Richard Staines speaks to Michael Sierra, Vice President of LEO Pharma’s Science and Tech Hub, about how the firm plans to chan